Australia markets closed

NeuroBo Pharmaceuticals, Inc. (NRBO)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
4.1500+0.0700 (+1.72%)
At close: 04:00PM EDT
4.2900 +0.14 (+3.37%)
After hours: 07:08PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 34.12M
Enterprise value 18.32M
Trailing P/E 13.83
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.39
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.43

Trading information

Stock price history

Beta (5Y monthly) -0.29
52-week change 31.12%
S&P500 52-week change 318.96%
52-week high 36.7500
52-week low 32.9000
50-day moving average 34.3086
200-day moving average 34.0423

Share statistics

Avg vol (3-month) 361.19k
Avg vol (10-day) 329.4k
Shares outstanding 58.22M
Implied shares outstanding 68.22M
Float 81.19M
% held by insiders 167.86%
% held by institutions 19.59%
Shares short (15 July 2024) 452.67k
Short ratio (15 July 2024) 40.46
Short % of float (15 July 2024) 40.98%
Short % of shares outstanding (15 July 2024) 40.64%
Shares short (prior month 14 June 2024) 458.54k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 331 Dec 2019
Ex-dividend date 4N/A
Last split factor 21:8
Last split date 321 Dec 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-52.18%
Return on equity (ttm)-108.42%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -20.24M
Net income avi to common (ttm)-16.58M
Diluted EPS (ttm)0.3000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)15.99M
Total cash per share (mrq)3.26
Total debt (mrq)187k
Total debt/equity (mrq)1.86%
Current ratio (mrq)2.46
Book value per share (mrq)2.05

Cash flow statement

Operating cash flow (ttm)-14.69M
Levered free cash flow (ttm)-16.63M